Want to see HK:9995 full AI Analyst Report?
RemeGen Co. Ltd. Class H (9995) AI Stock Analysis
Top Page
RemeGen Co. Ltd. Class H
(HKEX:9995)
The score is driven by strong recent financial performance (sharp profitability and cash-flow turnaround with low leverage) and a low P/E that suggests favorable valuation if earnings hold. Offsetting this, technical signals are weak, with the price below all key moving averages and negative MACD, indicating the market trend remains bearish despite improved fundamentals.
RemeGen Co. Ltd. Class H (9995) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 35.89B
- Dividend Yield
- ―
- Average Volume (3M)
- 2.68M
- Price to Earnings (P/E)
- 7.9
- Beta (1Y)
- 0.93
- Revenue Growth
- 292.84%
- EPS Growth
- ―
- Country
- Hong Kong
- Employees
- 3,048
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
RemeGen Co. Ltd. Class H Business Overview & Revenue Model
Company Description
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitaci...
How the Company Makes Money
RemeGen primarily makes money through the commercialization of its proprietary drug products, where revenue is generated from product sales (i.e., selling approved therapies into healthcare channels such as hospitals, pharmacies, and/or distributors,...
RemeGen Co. Ltd. Class H Financial Statement Overview
Summary
TTM results show a major profitability and cash-flow inflection (very high margins, strong operating/free cash flow, and much lower leverage). The key risk is durability: the company swung from multi-year losses and cash burn (2022–2025) to outsized profitability in a short window, suggesting results could be lumpy or influenced by non-recurring factors.
Income Statement
78PositiveBalance Sheet
72PositiveCash Flow
70Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.24B | 3.24B | 1.72B | 1.08B | 767.77M | 1.42B |
| Gross Profit | 7.60B | 2.82B | 1.37B | 822.99M | 497.84M | 1.36B |
| EBITDA | 5.26B | 431.72M | -1.12B | -1.25B | -805.70M | 402.05M |
| Net Income | 6.49B | 709.65M | -1.47B | -1.51B | -997.84M | 276.26M |
Balance Sheet | ||||||
| Total Assets | 10.54B | 7.25B | 5.50B | 5.53B | 6.02B | 4.16B |
| Cash, Cash Equivalents and Short-Term Investments | 5.51B | 2.42B | 759.53M | 709.07M | 2.07B | 1.76B |
| Total Debt | 292.23M | 2.20B | 2.67B | 1.26B | 165.03M | 102.78M |
| Total Liabilities | 1.65B | 3.64B | 3.51B | 2.09B | 1.04B | 712.79M |
| Stockholders Equity | 8.89B | 3.61B | 1.99B | 3.44B | 4.98B | 3.45B |
Cash Flow | ||||||
| Free Cash Flow | 3.83B | -140.08M | -1.38B | -2.35B | -2.02B | -353.71M |
| Operating Cash Flow | 3.96B | 54.75M | -1.11B | -1.50B | -1.26B | 263.63M |
| Investing Cash Flow | -2.44B | -203.49M | -248.24M | -817.65M | -841.56M | -637.95M |
| Financing Cash Flow | -1.63B | 537.67M | 1.39B | 978.31M | 2.43B | -626.90M |
RemeGen Co. Ltd. Class H Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9995, the sentiment is Negative. The current price of 64.85 is below the 20-day moving average (MA) of 67.32, below the 50-day MA of 73.41, and below the 200-day MA of 83.69, indicating a bearish trend. The MACD of -2.98 indicates Negative momentum. The RSI at 41.89 is Neutral, neither overbought nor oversold. The STOCH value of 55.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9995.
RemeGen Co. Ltd. Class H Peers Comparison
Overall Rating
- HK:999566Neutral
HK:996965Neutral
HK:269664.6Neutral
HK:996652Neutral
HK:992642Neutral
HK:187741.25Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:9995 | 66Neutral | HKD 51.82B | 7.89 | 105.60% | ― | 292.84% | ― |
| HK:9969 | 65Neutral | HKD 16.81B | 12.42 | 17.47% | ― | 146.27% | ― |
| HK:2696 | 65Neutral | HKD 26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% |
| HK:9966 | 52Neutral | HKD 6.06B | -30.68 | -10.27% | ― | -31.77% | -177.01% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9926 | 42Neutral | HKD 76.70B | -66.50 | -10.86% | ― | 42.47% | -15.80% |
| HK:1877 | 41Neutral | HKD 30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9995 | RemeGen Co. Ltd. Class H | 64.85 | -28.00 | -30.16% | |
| HK:9926 | Akeso, Inc. | 81.50 | -36.80 | -31.11% | |
| HK:9966 | Alphamab Oncology | 6.21 | -5.46 | -46.79% | |
| HK:9969 | InnoCare Pharma Ltd. | 11.25 | -3.37 | -23.05% | |
| HK:1877 | Shanghai Junshi Biosciences Co., Ltd. Class H | 15.26 | -11.44 | -42.85% | |
| HK:2696 | Shanghai Henlius Biotech, Inc. Class H | 49.06 | -20.04 | -29.00% |
RemeGen Co. Ltd. Class H Corporate Events
RemeGen Issues Unaudited 2026 Third-Quarter Report and Cautions Investors
RemeGen Co., Ltd. has released an unaudited third-quarter report for 2026 prepared under PRC accounting principles to meet STAR Market disclosure requirements, while reminding investors that these figures differ from International Financial Reporting...
RemeGen Sets Board Meeting to Approve Third-Quarter Results
RemeGen Co., Ltd., a Hong Kong-listed biopharmaceutical company incorporated in the People’s Republic of China, develops and commercializes innovative therapeutic products, serving investors who track its financial and R&D progress in the g...
RemeGen Deploys Idle Funds Into RMB670 Million SPDB Wealth Products
RemeGen Co., Ltd. has expanded its use of idle self-owned funds for cash management by purchasing additional wealth management products from SPDB Yantai Branch. On October 14, 2026, the company entered into two new agreements totaling RMB370 million,...
RemeGen Reshapes Company Secretariat and Hong Kong Representation Roles
RemeGen Co., Ltd. announced a change in its corporate governance structure, confirming that the Hong Kong Stock Exchange has recognized Mr. Tong Shaojing as having the requisite experience to serve as company secretary under applicable listing rules....
RemeGen Deploys Idle Funds Into Discloseable Wealth Management Products
RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong under stock code 9995, focuses on innovative biologic drug development and commercialization. Its capital-intensive operations are supported by self-owned funds and A-share...
RemeGen Delivers Surging Interim Revenue as Key Biologic Therapies Secure New Approvals and Milestones
RemeGen Co., Ltd. reported a sharp rise in interim revenue to RMB5,850.2 million for the six months ended June 30, 2026, a 435.74% increase year-on-year driven by robust sales of its commercial-stage drugs telitacicept and disitamab vedotin, as well...
RemeGen Sets Out Board Structure and Key Governance Committees
RemeGen Co., Ltd. has announced the current composition of its board of directors, comprising five executive directors, one non-executive director and three independent non-executive directors. The chairman of the board, together with the employee re...
RemeGen Commits US$100 Million of Idle Funds to OCBC Wealth Products in Discloseable Transaction
RemeGen Co., Ltd., a PRC-based biopharmaceutical company listed in Hong Kong, develops and commercializes innovative biologic therapies for autoimmune and oncology indications across domestic and global markets. The company leverages its listing to a...
RemeGen Sets Board Meeting to Approve Interim 2026 Results
RemeGen Co., Ltd. has scheduled a board meeting for August 24, 2026 to review and approve the interim results for the six months ended June 30, 2026. The company also plans to publish these interim results following board approval, a step that will p...
RemeGen Forecasts Major Profit Turnaround on Surging Drug Sales and AbbVie Licensing Deal
RemeGen Co., Ltd. has issued an inside information announcement estimating a sharp improvement in its financial performance for the six months ended June 30, 2026, under China Accounting Standards. The company expects operating revenue of about RMB5....
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 31, 2026